UNLABELLED: We present here a systematic analysis of lymphoma and MM patients recruited into 2 clinical trials or treated with radretumab according to compassionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab. METHODS: Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed lymphoma or multiple myeloma patients. RESULTS: In 14 of 18 patients, selective tumor uptake was found; 11 of 15 lymphoma patients, including 9 of 11 with Hodgkin lymphoma (HL), were eligible for R-RIT (a priori criteria-based target-to-bone marrow ratio > 10:1 for EudraCT no. 2005-000545 or > 4:1 for EudraCT no. 2007-007241-12 at dosimetric imaging). Two HL and 1 diffuse large B cell lymphoma patient achieved complete response; 1 HL patient had partial response. Both multiple myeloma patients receiving R-RIT experienced stabilization of disease. Therefore, the overall objective response rate was 40%. Uncomplicated grade 3-4 thrombocytopenia or leukocytopenia was observed in 5 R-RIT patients, lasting 4-129 d. CONCLUSION: R-RIT showed a favorable benefit and risk profile in advanced relapsed lymphoma patients and induced complete response in 2 heavily pretreated, relapsed HL patients and in 1 diffuse large B cell lymphoma patient. These results warrant further exploration of R-RIT in larger phase II clinical trials.
UNLABELLED: We present here a systematic analysis of lymphoma and MMpatients recruited into 2 clinical trials or treated with radretumab according to compassionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab. METHODS: Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed lymphoma or multiple myelomapatients. RESULTS: In 14 of 18 patients, selective tumor uptake was found; 11 of 15 lymphomapatients, including 9 of 11 with Hodgkin lymphoma (HL), were eligible for R-RIT (a priori criteria-based target-to-bone marrow ratio > 10:1 for EudraCT no. 2005-000545 or > 4:1 for EudraCT no. 2007-007241-12 at dosimetric imaging). Two HL and 1 diffuse large B cell lymphomapatient achieved complete response; 1 HL patient had partial response. Both multiple myelomapatients receiving R-RIT experienced stabilization of disease. Therefore, the overall objective response rate was 40%. Uncomplicated grade 3-4 thrombocytopenia or leukocytopenia was observed in 5 R-RITpatients, lasting 4-129 d. CONCLUSION:R-RIT showed a favorable benefit and risk profile in advanced relapsed lymphomapatients and induced complete response in 2 heavily pretreated, relapsed HL patients and in 1 diffuse large B cell lymphomapatient. These results warrant further exploration of R-RIT in larger phase II clinical trials.
Authors: L Angenendt; S Reuter; D Kentrup; A S Benk; F Neumann; J Hüve; A C Martens; C Schwöppe; T Kessler; L H Schmidt; T Sauer; C Brand; J-H Mikesch; G Lenz; R M Mesters; C Müller-Tidow; W Hartmann; E Wardelmann; D Neri; W E Berdel; C Roesli; C Schliemann Journal: Leukemia Date: 2017-06-30 Impact factor: 11.528
Authors: G Spitaleri; R Berardi; C Pierantoni; T De Pas; C Noberasco; C Libbra; R González-Iglesias; L Giovannoni; A Tasciotti; D Neri; H D Menssen; F de Braud Journal: J Cancer Res Clin Oncol Date: 2012-11-17 Impact factor: 4.553
Authors: Marcus Franz; Monika Matusiak-Brückner; Petra Richter; Katja Grün; Barbara Ziffels; Dario Neri; Hansjörg Maschek; Uwe Schulz; Alexander Pfeil; Christian Jung; Hans R Figulla; Jan Gummert; Alexander Berndt; André Renner Journal: J Mol Histol Date: 2014-05-03 Impact factor: 2.611
Authors: Luigi Aloj; Laura D'Ambrosio; Michela Aurilio; Anna Morisco; Ferdinando Frigeri; Corradina Caraco'; Francesca Di Gennaro; Gaetana Capobianco; Leonardo Giovannoni; Hans D Menssen; Dario Neri; Antonio Pinto; Secondo Lastoria Journal: Eur J Nucl Med Mol Imaging Date: 2014-01-17 Impact factor: 9.236